Table 1 Trial characteristics for included phase III studies of systemic anti-cancer therapy in advanced gastric, oesophageal or gastroesophageal cancer
n (Total n = 66) | % | |
|---|---|---|
Geographic Location | ||
Asian | 32 | 48 |
European | 15 | 23 |
Worldwide | 19 | 29 |
Disease Site | ||
Gastric | 56 | 86 |
Gastroesophageal Junction | 3 | 5 |
Oesophageal | 6 | 9 |
Line of Treatment | ||
≥ 1 | 42 | 64 |
≥ 2 | 21 | 32 |
≥ 3 | 3 | 4 |
Year of Publication | ||
1995–2004 | 7 | 12 |
2005–2014 | 25 | 38 |
2015- to date | 34 | 51 |
Median Age of Participants | 62 | (Range 18–94) |
Upper Age Restriction | ||
Yes | 21 | 32 |
No | 43 | 65 |
Not Specified | 2 | 3 |
Median Cut Off Age | 75 | (Range 65–80) |